America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
– How does AOH1996’s targeting of the PCNA protein enhance its effectiveness against cancer cells?
**Interview with Dr. Linda Malkas on the Development of AOH1996: A New Weapon Against Cancer**
**Editor**: Welcome, Dr. Linda Malkas, and thank you for joining us today. You and your team at City of Hope have made significant strides in cancer treatment with the development of AOH1996. Can you explain what makes this treatment unique?
**Dr. Malkas**: Thank you for having me. AOH1996 is unique because it targets a specific mutation in the PCNA protein found only in cancer cells. Think of PCNA as an airline terminal that oversees many flights; in our case, it manages cellular replication. AOH1996 disrupts this process, effectively shutting down the cancerous “flights” without harming normal cells.
**Editor**: That’s an interesting analogy. You mentioned the drug has shown effectiveness across various cancer types. Which types of cancers have you tested it on?
**Dr. Malkas**: In our studies, we’ve tested AOH1996 on breast, prostate, brain, ovarian, cervical, skin, and lung cancers. During our research, we examined over 70 different cancer cell lines, and the results were promising in selectively killing cancer cells while sparing healthy ones.
**Editor**: What are the next steps for AOH1996 now that it’s shown promise in lab tests?
**Dr. Malkas**: The next crucial step is to move into clinical trials with human participants. We’ve seen the potential in a controlled laboratory setting, and now we need to evaluate its safety and efficacy in a clinical environment.
**Editor**: That sounds very hopeful for cancer patients. How long do you anticipate it will take to move from the lab to clinical trials?
**Dr. Malkas**: While I cannot provide a specific timeline, the transition to clinical trials typically takes several months to a few years due to regulatory processes and the need for thorough safety assessments. However, our team is committed to expediting this process as much as we can.
**Editor**: Thank you for shedding light on this innovative treatment, Dr. Malkas. It’s reassuring to hear about progress in cancer therapies.
**Dr. Malkas**: Thank you for your interest, and I truly hope that our work will contribute to new, effective treatments for patients battling cancer.
**Editor**: We look forward to following the progress of AOH1996. Thank you for your time.